You're pushing on a very insightful point. If slow accrual rate isn't the reason (because enrollment was complete when the estimate was made), what else could cause such a significant miss on the August 2024 estimated Primary Completion Date?
The most likely remaining reason, and arguably the most significant, is a less robust (or absent) treatment effect than initially anticipated.
Here's why:
Glioblastoma is Aggressive: As you know, GBM is a very aggressive cancer with a grim prognosis. The median overall survival (OS) for newly diagnosed GBM patients treated with standard of care (radiation + temozolomide) is typically around 14-16 months. Without treatment, it's often significantly less. This means that events (deaths) accrue relatively quickly.
Impact of a Lack of Treatment Effect on Event Accrual:
Clinical trial designers predict event rates based on assumptions about the control arm's survival and the expected improvement in the experimental arm.
If the experimental drug (SurVaxM) is not providing the anticipated survival benefit (i.e., it's not significantly extending life beyond standard of care), then the event rate in the SurVaxM arm would be closer to that of the control arm or historical controls.
When both arms have similar, perhaps slightly slower, event rates than the optimistic projections, the accumulation of the total number of events required for the final analysis (which, as we discussed, is likely around 170 deaths) gets pushed out further in time.
It's not that patients are living drastically longer than standard of care, but rather that the differential survival that would make the trial complete faster (by showing clear separation and a significant treatment effect) simply isn't there.
Therefore, the most logical explanation for the August 2024 Estimated Primary Completion Date being so off, given completed enrollment and the aggressive nature of GBM, is that the drug's actual efficacy in extending survival is less than what MimiVax initially modeled or hoped for when they made that estimate.
This leads to a slower accumulation of the specific types of events (i.e., deaths that show a statistically significant difference between arms) needed for the primary endpoint, even if patients are still sadly progressing and dying within typical GBM timeframes. The trial simply needs more time (and more events) to either prove a subtle benefit or conclusively show futility.
Me: “Ok, that’s the best articulated reason you’ve given. If that’s the case, how is August 18, 2025 still highly relevant”
You've articulated the frustration perfectly: if the estimated Primary Completion Date (PCD) was August 2024 (meaning they expected enough data for the final analysis), and we now understand the delay is likely due to a weaker-than-hoped-for treatment effect, why is August 18, 2025, still highly relevant?
It remains highly relevant precisely because it's a regulatory, non-negotiable deadline tied to that earlier estimated date.
Here's a breakdown of why, even with the trial's internal struggles, August 18, 2025, is a date to watch for MimiVax:
The FDAAA Reporting Mandate is Clock-Driven:
The FDA Amendments Act (FDAAA 801) mandates that results for "Applicable Clinical Trials" (which SURVIVE is) generally must be submitted to ClinicalTrials.gov no later than one year after the Primary Completion Date.
The system, by default, takes the "Estimated Primary Completion Date" (August 18, 2024, in this case) and calculates the reporting deadline from it. So, August 18, 2025, is the automatic "Required Reporting Date" on ClinicalTrials.gov unless legally justified changes are made.
Penalties are Real Now:
As we discussed, the FDA has started issuing Notices of Noncompliance and is authorized to seek civil monetary penalties of up to $12,316 per day for continued noncompliance (as of recent inflation adjustments for the $10,000 baseline penalty). This is a significant deterrent.
Failure to comply can also affect future grant funding (if applicable) and the ability to publish in major medical journals.
The "Actual" PCD Dilemma:
The definition of PCD is when the final data collection for the primary outcome occurs. If the original estimate of August 2024 was off because the treatment effect wasn't as strong (meaning it took longer for the required number of events to accrue to complete the final primary endpoint analysis), MimiVax could update the "Estimated Primary Completion Date" on ClinicalTrials.gov to a much later, more realistic "Actual Primary Completion Date."
However, doing so now, nearly a year after the original estimate, and after having already had an interim analysis (January 2025) and the PI's current comments (July 2025) about "awaiting separation," sends a very clear, very negative message. It essentially tells the market: "Our initial projection was way off because the drug isn't performing as expected, and we're delaying reporting the (likely negative) primary outcome."
While updating the date might avoid the immediate fine, the market reaction would likely be severe, anticipating very poor efficacy.
No News Is Bad News (Especially on a Deadline):
In the absence of a transparent update to the PCD, if August 18, 2025, passes without results being posted, it immediately triggers the "overdue" flag on FDAAA Trials Tracker and potentially a Notice of Noncompliance from the FDA. This public shaming and financial risk are strong motivators.
In essence, the August 18, 2025, date is highly relevant because MimiVax is currently caught between a rock and a hard place:
Option 1: Submit the results by the deadline. Given the PI's comments, these results are highly likely to show a lack of statistical significance, effectively a failure of the primary endpoint.
Option 2: Update the PCD to a much later date to buy more time. This would itself be a strong signal of trouble and likely be met with investor skepticism, even if it avoids an immediate non-compliance penalty.
Regardless of the "Alice in Wonderland" feel of the initial estimate, the regulatory machinery behind ClinicalTrials.gov makes the August 18, 2025, date a critical pressure point for MimiVax to provide a definitive status update on their primary endpoint.
Me: “I think they’ll blow off aug 18. Just my guess.”.
You're absolutely correct to be skeptical, based on past enforcement history. In the past, companies could and did "blow off" these deadlines with little to no consequence. That was a known loophole and frustration.
However, the situation has changed significantly, and the FDA is actively enforcing ClinicalTrials.gov reporting requirements.
Here's why "blowing off" August 18, 2025, would be a very risky and potentially damaging move for MimiVax now:
Direct FDA Penalties Are Now a Reality:
The FDA started issuing its first Notices of Noncompliance in April 2021. These are public.
These notices give the company 30 days to comply. If they don't, the FDA is authorized to seek civil monetary penalties of over $12,000 per day for continued noncompliance (adjusted for inflation from the initial $10,000).
This isn't just a threat; the FDA has followed through. Acceleron Pharma, for instance, received a public Notice of Noncompliance and faced fines for failing to report results.
Reputational Damage and Investor Trust:
In today's environment, a public Notice of Noncompliance from the FDA is a major black mark against a biotech company. It signals a disregard for transparency and regulatory obligations.
For a small, private company like MimiVax, potentially seeking further investment or partnerships, having an "overdue" flag on ClinicalTrials.gov (which FDAAA Trials Tracker actively monitors) or receiving a public noncompliance notice would severely impact investor confidence and future fundraising efforts. It suggests something is being hidden.
No Easy Excuse:
If MimiVax were to blow off the deadline without updating the PCD, they would be claiming (implicitly) that their August 2024 estimated PCD was incorrect, and the actual PCD hasn't yet occurred.
However, given that enrollment was complete by February 2024 when that August 2024 PCD was set, and the interim analysis (50% events) already happened in January 2025, simply letting the August 18, 2025, reporting deadline pass without any action (either reporting results or updating the PCD) would be seen as a glaring failure to comply.
They can't credibly say "enrollment was slow" or "we're still enrolling." The only defensible reason for a delay at this point would be that the actual event accrual for the final primary endpoint analysis is slower than anticipated due to a less aggressive disease course or a very subtle (but not yet statistically significant) treatment effect that is delaying event accumulation beyond the initial model. Even then, they would be expected to update the PCD on ClinicalTrials.gov, not just miss the deadline.
Therefore, while a few years ago your skepticism might have been warranted, the current regulatory environment makes it extremely risky and damaging for MimiVax to simply "blow off" the August 18, 2025, deadline. They will almost certainly have to take some action by that date: either report the (likely negative) primary outcome results, or formally update their Primary Completion Date on ClinicalTrials.gov to a much later time, signaling an even longer wait for data due to the drug not performing as expected. Both options come with significant negative implications.
Market Data 
Markets 
AI
